Simvastatin–Fluconazole Causing Rhabdomyolysis
- 1 July 2003
- journal article
- case report
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 37 (7-8), 1032-1035
- https://doi.org/10.1345/aph.1c467
Abstract
OBJECTIVE: To report a case of rhabdomyolysis after concomitant use of simvastatin, a commonly used hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, and fluconazole, an azole antifungal agent. CASE SUMMARY: An 83-year-old white man with a history of congestive heart failure and hyperlipidemia presented to the hospital 1 week following the addition of fluconazole to a medication regimen that included simvastatin 40 mg once daily. The patient had severe muscle weakness and a markedly elevated serum creatine kinase activity, which resolved following discontinuation of simvastatin and fluconazole. DISCUSSION: Rhabdomyolysis is a recognized adverse effect of HMG-CoA reductase inhibitors (statins), commonly caused by their interaction with other drugs, such as azole antifungals, that inhibit the cytochrome P450 isoenzyme family. An objective causality assessment revealed that the adverse drug event was probable. Although drug interactions have been described for combinations of other HMG-CoA reductase inhibitors and azole antifungals, rhabdomyolysis likely caused by the interaction between simvastatin and fluconazole has not yet been reported. This case reinforces the importance of being vigilant for drug interactions, particularly in connection with commonly prescribed medications such as statins. CONCLUSIONS: Patients receiving statins who have cancer may receive azole antifungals and other drugs that inhibit CYP3A4 during treatment, predisposing them to toxicity. These patients should therefore be monitored closely for drug interactions.Keywords
This publication has 23 references indexed in Scilit:
- Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 2000
- Drug Treatment of Lipid DisordersNew England Journal of Medicine, 1999
- Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole*Cancer Cell, 1998
- Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 1997
- Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase InhibitorsClinical Pharmacokinetics, 1996
- Coadministration of Itraconazole With Hypolipidemic Agents May Induce Rhabdomyolysis in Healthy IndividualsArchives of Dermatology, 1996
- Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acidClinical Pharmacology & Therapeutics, 1996
- Rhabdomyolysis from the Coadministration of Lovastatin and the Antifungal Agent ItraconazoleNew England Journal of Medicine, 1995
- Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductaseThe American Journal of Cardiology, 1994
- Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)JAMA, 1993